Maria Shipkova

Maria Shipkova

Auto-generated profile, based on publicly available information

Maria Shipkova

Zentralinstitut für Klinische Chemie und Laboratoriumsmedizin, Klinikum Stuttgart, Stuttgart, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
MSMaria Shipkova
Maria Shipkova
DHDennis A. Hesselink
Dennis A. Hesselink
DHDavid W. Dsc(Med) Holt
David W. Dsc(Med) Holt
EBEliane M. Billaud
Eliane M. Billaud
TGTeun van Gelder
Teun van Gelder
PMPierre Marquet
Pierre Marquet
In 2014, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology called a meeting of international experts to provide recommendations to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice. EVR is a potent inhibitor of the mammalian target of rapamycin, approved for the prevention of organ transplant rejection and for the treatment of various types of cancer and tuberous sclerosis complex. EVR fulfills the prerequisites for TDM, having a narrow therapeutic range, high interindividual pharmacokinetic variability, and established drug exposure–response relationships. EVR trough concentrations (C0) demonstrate a good relationship with overall exposure, providing a simple and reliable index for TDM. Whole-blood samples should be used for measurement of EVR C0, and sampling times should be standardized to occur within 1 hour before the next dose, which should be taken at the same time everyday and preferably without food. In transplantation settings, EVR should be generally targeted to a C0 of 3–8 ng/mL when used in combination with other immunosuppressive drugs (calcineurin inhibitors and glucocorticoids); in calcineurin inhibitor-free regimens, the EVR target C0 range should be 6–10 ng/mL. Further studies are required to determine the clinical utility of TDM in nontransplantation settings. The choice of analytical method and differences between methods should be carefully considered when determining EVR concentrations, and when comparing and interpreting clinical trial outcomes. At present, a fully validated liquid chromatography tandem mass spectrometry assay is the preferred method for determination of EVR C0, with a lower limit of quantification close to 1 ng/mL. Use of certified commercially available whole-blood calibrators to avoid calibration bias and participation in external proficiency-testing programs to allow continuous cross-validation and proof of analytical quality are highly recommended. Development of alternative assays to facilitate on-site measurement of EVR C0 is encouraged.

1 February 2006 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
MSMaria Shipkova
Maria Shipkova
KLKristin Lorenz
Kristin Lorenz
MOMichael Oellerich
Michael Oellerich
EWEberhard Wieland
Eberhard Wieland
NANicolas von Ahsen
Nicolas von Ahsen
Background: Inosine triphosphate (ITP) pyrophosphohydrolase (ITPA) catalyzes the pyrophosphohydrolysis of ITP/dITP and xanthosine triphosphate to prevent incorporation of unusual nucleotides into RNA and DNA. Important mutations leading to enzyme deficiency are 94C>A and IVS2 + 21A>C. An association between ITPA 94C>A and adverse reactions during azathioprine treatment has been shown. To investigate the ITPA phenotype, an HPLC procedure was developed and phenotype-genotype correlations were assessed. Methods: The enzymatic conversion of ITP to inosine monophosphate (IMP) was terminated by perchloric acid and saturated dipotassium hydrogen phosphate. We quantified the IMP at 262 nm after separation on an Aqua perfect C18 column using 20 mmol/L phosphate buffer, pH 2.5. We also genotyped samples for ITPA 94C>A and IVS2 + 21A>C by real-time fluorescence PCR. Results: The assay was linear to 3 mmol/L IMP [∼500 μmol/(g Hb · h)] with a lower limit of quantification of 4 μmol/L [∼0.5 μmol/(g Hb · h)]. With IMP-enriched samples, within- and between-day imprecision was ≤3.6% and ≤4.9%, respectively, and the inaccuracy was ≤5.2%. With pooled erythrocytes, within- and between-day imprecision was 3.8% and 7.5%, respectively. ITPA activity in 130 healthy controls was between A) and 0.131 (IVS2 + 21A>C). When we used a cutoff of 125 μmol IMP/(g Hb · h), phenotyping detected all 94C>A mutant cases, all 94C>A and IVS2 + 21A>C compound heterozygotes, all IVS2 + 21A>C homozygotes, and 6 of 24 IVS2 + 21A>C heterozygote-only cases. A novel IVS2 + 68T>C mutation was also found. Conclusions: The HPLC procedure provides an excellent ITPA phenotype-genotype correlation and led to the discovery of a novel IVS2 + 68T>C mutation. The method could facilitate investigation of the role of ITPA activity for drug toxicity during thiopurine therapy.

1 September 2016 in Clinical Biochemistry
Verified
Journal Article
Closed access
MSMaria Shipkova
Maria Shipkova
DSDobrin Avramov Svinarov
Dobrin Avramov Svinarov

29 September 2005 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
MSMaria Shipkova
Maria Shipkova
VAVictor William Armstrong
Victor William Armstrong
MOMichael Oellerich
Michael Oellerich
EWEberhard Wieland
Eberhard Wieland
Mycophenolate mofetil (MMF) received its first approval for the prevention of renal allograft rejection in 1995 and has now become the most frequently used antiproliferative agent in maintenance immunosuppressive therapy for kidney, pancreas, liver and heart transplantation. In addition, its use for the treatment of autoimmune diseases steadily increases. This review focuses on the miscellaneous pharmacodynamic properties of the drug, its pharmacokinetics in healthy subjects, recipients of different organ transplants and combination therapy with other pharmaceuticals, as well as its safety profile. The immunosuppressive activity of MMF is thought to derive mainly from the potent and selective inhibition of purine synthesis in both T and B lymphocytes. In contrast to other immunosuppressants on the market, it is metabolised primarily by glucuronidation and lacks nephrotoxicity, cardiovascular toxicity or diabetogenic potential, thus making it a suitable candidate for combination regimens. The most importan...

1 March 2002
Verified
Journal Article
Closed access
LWLutz T Weber
Lutz T Weber
MSMaria Shipkova
Maria Shipkova
VAVictor W Armstrong
Victor W Armstrong
NWNatalie Wagner
Natalie Wagner
ESEkkehard Schütz
Ekkehard Schütz
BTBurkhard Tönshoff
Burkhard Tönshoff

1 March 2016 in Clinical Biochemistry
Verified
Journal Article
Closed access
EWEberhard Wieland
Eberhard Wieland
MSMaria Shipkova
Maria Shipkova